elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Pricing
Log in
Sign up
Home
/
Subjects
/
Standard of care
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Standard of care
RIS
0.008
(Research Intensity Score)
Papers
1442
Top papers
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
2022 · 1141 citations
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
2023 · 670 citations
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
2022 · 781 citations
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial
2024 · 157 citations
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
2020 · 1494 citations
Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell Lung Cancer
2025 · 74 citations
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance
2023 · 225 citations
Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis
2025 · 63 citations
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update
2025 · 84 citations
Newest papers
Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.
2026 · 12 citations
Chemoresistance in ovarian cancer (I)
2026 · 8 citations
Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell Lung Cancer
2025 · 74 citations
Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis
2025 · 63 citations
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update
2025 · 84 citations
NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.
2025 · 58 citations
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study
2025 · 45 citations
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).
2025 · 52 citations
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
2025 · 49 citations
Browse all papers →
Standard of care's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Standard of care's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link